[go: up one dir, main page]

MX2022001019A - Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38). - Google Patents

Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).

Info

Publication number
MX2022001019A
MX2022001019A MX2022001019A MX2022001019A MX2022001019A MX 2022001019 A MX2022001019 A MX 2022001019A MX 2022001019 A MX2022001019 A MX 2022001019A MX 2022001019 A MX2022001019 A MX 2022001019A MX 2022001019 A MX2022001019 A MX 2022001019A
Authority
MX
Mexico
Prior art keywords
heterobicyclic
amides
inhibitors
cancer
useful
Prior art date
Application number
MX2022001019A
Other languages
English (en)
Inventor
Nicholas Robert Perl
Kevin Wayne Kuntz
Melissa Marie Vasbinder
Laurie B Schenkel
Jennifer Downing
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of MX2022001019A publication Critical patent/MX2022001019A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Amidas heterobicíclicas y compuestos relacionados que son inhibidores del CD38 y son útiles para el tratamiento del cáncer.
MX2022001019A 2019-07-31 2020-07-30 Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38). MX2022001019A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962880923P 2019-07-31 2019-07-31
US201962951604P 2019-12-20 2019-12-20
US202063034750P 2020-06-04 2020-06-04
PCT/US2020/044156 WO2021021986A1 (en) 2019-07-31 2020-07-30 Heterobicyclic amides as inhibitors of cd38

Publications (1)

Publication Number Publication Date
MX2022001019A true MX2022001019A (es) 2022-02-22

Family

ID=72139677

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2022001019A MX2022001019A (es) 2019-07-31 2020-07-30 Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
MX2025003444A MX2025003444A (es) 2019-07-31 2022-01-25 Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)
MX2025003445A MX2025003445A (es) 2019-07-31 2022-01-25 Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2025003444A MX2025003444A (es) 2019-07-31 2022-01-25 Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)
MX2025003445A MX2025003445A (es) 2019-07-31 2022-01-25 Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)

Country Status (12)

Country Link
US (3) US11535621B2 (es)
EP (1) EP4003980A1 (es)
JP (2) JP7721501B2 (es)
KR (1) KR20220061958A (es)
CN (2) CN114423753B (es)
AU (1) AU2020321956A1 (es)
BR (1) BR112022001291A2 (es)
CA (1) CA3147902A1 (es)
IL (2) IL289878B1 (es)
MX (3) MX2022001019A (es)
TW (1) TWI891649B (es)
WO (1) WO2021021986A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022001019A (es) 2019-07-31 2022-02-22 Ribon Therapeutics Inc Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
TW202128677A (zh) * 2019-10-30 2021-08-01 美商米突倍基公司 Cd38抑制劑
WO2022077034A1 (en) * 2020-10-09 2022-04-14 Napa Therapeutics Ltd. Heteroaryl amide inhibitors of cd38
JP7777596B2 (ja) 2021-01-29 2025-11-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３８阻害剤としてのキノリン及びアザキノリン
EP4330247A4 (en) * 2021-04-30 2025-05-28 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as cd38 inhibitors
WO2023288195A1 (en) * 2021-07-12 2023-01-19 Cytokinetics, Inc. Cd38 modulators and methods of use thereof
CN116041344A (zh) * 2021-10-28 2023-05-02 北京望实智慧科技有限公司 双环杂芳基甲酰胺化合物作为sos1抑制剂
EP4430034A1 (en) 2021-11-09 2024-09-18 Cerevance, Inc. N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors
CN114306366B (zh) * 2021-11-30 2023-01-06 合肥康诺生物制药有限公司 含nad和cd38抑制剂的药物组合物及其用途
WO2023098699A1 (en) * 2021-12-01 2023-06-08 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as cd38 inhibitors
GB202207721D0 (en) * 2022-05-25 2022-07-06 Cerevance Ltd Novel Compounds
EP4567035A1 (en) * 2022-08-05 2025-06-11 Nextgen Bioscience Co., Ltd. Novel compound as hypoxia-inducible factor 1(hif-1) inhibitor or vascular endothelial growth factor (vegf) inhibitor, and pharmaceutical composition comprising same
CN115825297B (zh) * 2022-11-11 2025-03-28 武汉海特生物创新医药研究有限公司 一种(s)-3-氨基哌啶-2,6-二酮盐酸盐对映异构体的检测方法
GB202307426D0 (en) * 2023-05-18 2023-07-05 Cerevance Inc Novel compounds
WO2024236316A1 (en) * 2023-05-18 2024-11-21 Cerevance, Inc. 3-carbonyl imidazo[1,5-a]pyridine derivatives for use as cd38 inhibitors for the treatment of cns disorders
WO2024254396A1 (en) * 2023-06-07 2024-12-12 Flagship Pioneering Innovations, Vi, Llc Condensed azines as inhibitors of cyclic adp ribose hydrolase

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101451290B1 (ko) * 2006-10-19 2014-10-15 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
EA022458B1 (ru) 2009-12-28 2016-01-29 Дженерал Инкорпорейтед Ассошиэйшн Фарма Вэлли Проджект Саппортинг Организейшн 1,3,4-оксадиазол-2-карбоксамидное соединение
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
JP5908493B2 (ja) * 2010-12-01 2016-04-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インドール
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9073924B2 (en) 2011-09-13 2015-07-07 Glaxosmithkline Llc Azaindazoles
TWI713752B (zh) * 2011-10-19 2020-12-21 標誌製藥公司 以ｔｏｒ激酶抑制劑治療癌症
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
KR20140095073A (ko) 2011-11-04 2014-07-31 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 치료 방법
EP2817029B1 (en) * 2012-02-24 2019-07-10 Signal Pharmaceuticals, LLC Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
US20150164910A1 (en) 2012-06-15 2015-06-18 The Regents Of The University Of Califonia Antiviral compounds and methods of use
US20150216168A1 (en) 2012-09-05 2015-08-06 Bayer Cropscience Ag Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress
WO2014159837A1 (en) 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
CN105017221B (zh) 2014-04-30 2019-05-28 中国医学科学院药物研究所 苯并咪唑衍生物及其制法和药物组合物与用途
BR112017011642A2 (pt) 2014-12-03 2018-03-06 Glaxosmithkline Ip No 2 Ltd composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.
US11059817B2 (en) * 2015-09-23 2021-07-13 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
WO2018151830A1 (en) * 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
US11180498B2 (en) * 2017-09-27 2021-11-23 The Regents Of The University Of California Substituted pyrrolo[2,3-b]pyridines, pyrazolo[3,4-d]pyrimidines and [1,2,3]triazolo[4,5-b]pyridines as potent antivirals
MX2022001019A (es) 2019-07-31 2022-02-22 Ribon Therapeutics Inc Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
TW202128677A (zh) 2019-10-30 2021-08-01 美商米突倍基公司 Cd38抑制劑
CA3179589A1 (en) 2020-04-07 2021-10-14 Mitobridge, Inc. Cd38 inhibitors
JP7777596B2 (ja) 2021-01-29 2025-11-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３８阻害剤としてのキノリン及びアザキノリン

Also Published As

Publication number Publication date
CN114423753A (zh) 2022-04-29
US20230312586A1 (en) 2023-10-05
JP7721501B2 (ja) 2025-08-12
BR112022001291A2 (pt) 2022-06-21
MX2025003444A (es) 2025-05-02
US20210032251A1 (en) 2021-02-04
IL289878A (en) 2022-03-01
IL324885A (en) 2026-01-01
EP4003980A1 (en) 2022-06-01
TWI891649B (zh) 2025-08-01
KR20220061958A (ko) 2022-05-13
TW202120496A (zh) 2021-06-01
US11535621B2 (en) 2022-12-27
US11987584B2 (en) 2024-05-21
JP2025160384A (ja) 2025-10-22
US12398146B2 (en) 2025-08-26
CN114423753B (zh) 2024-09-17
CN119431323A (zh) 2025-02-14
WO2021021986A1 (en) 2021-02-04
CA3147902A1 (en) 2021-02-04
JP2022542396A (ja) 2022-10-03
MX2025003445A (es) 2025-05-02
US20240368167A1 (en) 2024-11-07
IL289878B1 (en) 2026-01-01
AU2020321956A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
MX2025003444A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12016501546B1 (en) Cyclopropylamines as lsd1 inhibitors
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
PH12015502028A1 (en) Ido inhibitors
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
PH12021552588A1 (en) Cd73 inhibitors
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
WO2019023315A3 (en) Rac inhibitors
MX2023008701A (es) Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38).
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения